2Marks R,Borton SP,Shuttleworth D,et a/.Assessment of disease progress in psoriasis[J].Arch Dermatol, 1989,125 (2) : 235-240.
3Capon F,Burden AD,Trembath RC,et o1.Psoriasis and other complex trait dermatoses:from loci to functional pathways[J].Invest Dermatol, 201,132 (3pt2) : 915-922.
4Chen H,Poon A,Yeung C,et a/.Agenetic risk score combin- ing tenpsoriasis risk loci improves disease prediction [J]. PLoS One, 2011,6 (4) : e 19454.
5Tones T, Bettencourt N, Ferreira J,et d.Influence of TNF-ct gene polymorphisms in coronary artery calcification in psoriasis patients[J].Eur Acad dermatol Venereol,2016,30 (1) : 191-193.
6Rasmy H, Mikhael N, Ismail S.Interleukin- 18 expression and the response to treatment in patients with psoriasis[J]. Arch Med Sci,2011,7(4):713-719.
7Asadullah K,Friedrich M,Hanneken S,et a/.Effects of systemic interleukin-10 therapy on psoriatic skin le- sions : histologic immunohistologic, and molecular biology findings[J].Invest Dermatol, 2001,116 (5) : 721-727.
8Carter NA,Rosser EC,Mauri C.Interleukin-10 produced by B cells is crucial for the suppression of Thl7/Thl re- sponses, induction of T regulatory type 1 cells and reduc- tio of collagen-induced arthritis[J].Arthritis Res Ther, 2012,14(1) :R32.
